{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T02:41:00Z","timestamp":1789267260098,"version":"build-2803163510"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T00:00:00Z","timestamp":1666224000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002915","name":"Fondation pour la Recherche M\u00e9dicale","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002915","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    Autoantibodies (Abs) are biomarkers for many disease conditions and are increasingly used to facilitate diagnosis and treatment decisions. To guarantee high sensitivity and specificity, the choice of their detection method is crucial.\n                    <jats:italic>Via<\/jats:italic>\n                    cell-based assays, we recently found 21 patients with neurological diseases positive for antibodies against argonaute (AGO), 10 of which having a neuropathy (NP). Here, we established a simple and conformation-sensitive ELISA with the aim to distinguish between AGO1 Abs against conformational epitopes and non-conformational epitopes and to reveal further characteristics of AGO1 antibodies in NP and autoimmune disease (AID). In a retrospective multicenter case\/control and observational study, we tested 434 patients with NP, 274 disease controls with AID, and 116 healthy controls (HC) for AGO1 Abs\n                    <jats:italic>via<\/jats:italic>\n                    conformation-stabilizing ELISA. Seropositive patients were also tested for conformation-specificity\n                    <jats:italic>via<\/jats:italic>\n                    comparative denaturing\/stabilizing ELISA (CODES-ELISA), CBA positivity, AGO1 titers and IgG subclasses, and AGO2 reactivity. These parameters were statistically compared among different epitope-specific patient groups. We found Abs in 44 patients, including 28\/434 (6.5%) NP, 16\/274 (5.8%) AID, and 0\/116 (0%) HC. Serum reactivity was consistently higher for AGO1 than AGO2. Globally among the 44 AGO1 Abs-positive patients, 42 were also tested in CBA for AGO1 Abs positivity and 15 (35.7%) were positive. Furthermore, 43 were tested for conformation-specificity and 32 (74.4%) bound a conformational epitope. Among the subgroups of highly positive patients (ELISA z-score &amp;gt;14) with sera binding conformational epitopes (n=23), 14 patient sera were also CBA positive and 9 bound a second conformational but CBA-inaccessible epitope. A third, non-conformational epitope was bound by 11\/43 (15.6%). Among the epitope-specific patient subgroups, we found significant differences regarding the Abs titers, IgG subclass, and AGO2 reactivity. When comparing AGO1 Abs-positive NP versus AID patients, we found the conformation-specific and CBA inaccessible epitope significantly more frequently in AID patients. We conclude that 1) conformational ELISA was more sensitive than CBA in detecting AGO1 Abs, 2) serum reactivity is higher for AGO1 than for AGO2 at least for NP patients, 3) AGO1 Abs might be a marker-of-interest in 6.5% of NP patients, 4) distinguishing epitopes might help finding different patient subgroups.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2022.972161","type":"journal-article","created":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T01:06:27Z","timestamp":1666227987000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["Conformation-stabilizing ELISA and cell-based assays reveal patient subgroups targeting three different epitopes of AGO1 antibodies"],"prefix":"10.3389","volume":"13","author":[{"given":"Christian P.","family":"Moritz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le-Duy","family":"Do","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yannick","family":"Tholance","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Baptiste","family":"Vallayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Rogemond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastien","family":"Joubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Ferraud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coralie","family":"La Marca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Philippe","family":"Camdessanch\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Honnorat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Christophe","family":"Antoine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/FIMMU.2022.813926","article-title":"Immune-mediated cerebellar ataxia associated with neuronal surface antibodies","volume":"13","author":"Jia","year":"2022","journal-title":"Front Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/FIMMU.2021.785247","article-title":"Anti-neuronal IgG4 autoimmune diseases and IgG4-related diseases may not be part of the same spectrum: A comparative study","volume":"12","author":"Endmayr","year":"2022","journal-title":"Front Immunol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/FIMMU.2021.666114","article-title":"False positive results in SARS-CoV-2 serological tests for samples from patients with chronic inflammatory diseases","volume":"12","author":"Kharlamova","year":"2021","journal-title":"Front Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1093\/JALM\/JFAB133","article-title":"Utility of live cell-based assays for autoimmune neurology diagnostics","volume":"7","author":"Woodhall","year":"2022","journal-title":"J Appl Lab Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/J.AUTREV.2012.03.001","article-title":"Anti-NMDA receptor encephalitis. the disorder, the diagnosis and the immunobiology","volume":"11","author":"Peery","year":"2012","journal-title":"Autoimmun Rev"},{"key":"B6","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/J.JNEUROIM.2011.12.020","article-title":"Identification of continuous epitopes of HuD antibodies related to paraneoplastic diseases\/small cell lung cancer","volume":"243","author":"Trier","year":"2012","journal-title":"J Neuroimmunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/BRAINCOMMS\/FCAA059","article-title":"Parent a v Et al High-resolution epitope mapping of anti-hu and anti-yo autoimmunity by programmable phage display","volume":"2","author":"O\u2019Donovan","year":"2020","journal-title":"Brain Commun"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001032","article-title":"Argonaute autoantibodies as biomarkers in autoimmune neurologic diseases","volume":"8","author":"Do","year":"2021","journal-title":"Neurology(R) Neuroimmunology Neuroinflamm"},{"key":"B9","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/978-1-4614-5107-5_4","article-title":"Autoantibodies to argonaute 2 (su antigen)","volume":"768","author":"Satoh","year":"2013","journal-title":"Adv Exp Med Biol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2017.06.022","article-title":"Autoantibodies to Su\/Argonaute 2 in Japanese patients with inflammatory myopathy","volume":"471","author":"Ogawa-Momohara","year":"2017","journal-title":"Clinica Chimica Acta"},{"key":"B11","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.nbt.2020.08.007","article-title":"Proper definition of the set of autoantibody-targeted antigens relies on appropriate reference group selection","volume":"60","author":"Moritz","year":"2021","journal-title":"New Biotechnol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/prca.201800157","article-title":"Completing the immunological fingerprint by refractory proteins: Autoantibody screening via an improved immunoblotting technique","volume":"13","author":"Moritz","year":"2019","journal-title":"Proteomics - Clin Appl"},{"key":"B13","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1136\/jnnp-2019-321849","article-title":"Clinical characterisation of sensory neuropathy with anti-FGFR3 autoantibodies","volume":"91","author":"Tholance","year":"2020","journal-title":"J Neurology Neurosurg Psychiatry"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2019.01.004","article-title":"Reducing the risk of misdiagnosis of indirect ELISA by normalizing serum-specific background noise: The example of detecting anti-FGFR3 autoantibodies","volume":"466","author":"Moritz","year":"2019","journal-title":"J Immunol Methods"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780271108","article-title":"Characterization of a new antigen-antibody system (su) in patients with systemic lupus erythematosus","volume":"27","author":"Treadwell","year":"1984","journal-title":"Arthritis Rheumatism"},{"key":"B16","doi-asserted-by":"publisher","first-page":"R87","DOI":"10.1186\/AR1959","article-title":"Autoimmune targeting of key components of RNA interference","volume":"8","author":"Jakymiw","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.679613","article-title":"Autoantibody discovery, assay development and adoption: Death valley, the Sea of survival and beyond","volume":"12","author":"Fritzler","year":"2021","journal-title":"Front Immunol"},{"key":"B18","article-title":"Autoantibodies to a miRNA-binding protein Argonaute2 (Su antigen) in patients with hepatitis c virus infection","volume":"28","author":"V\u00e1zquez-Del Mercado","year":"2010","journal-title":"Clin Exp Rheumatol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1080\/08923973.2021.1910833","article-title":"Presence of anti-TIF-1\u03b3, anti-Ro52, anti-SSA\/Ro60 and anti-Su\/Ago2 antibodies in breast cancer: A cross-sectional study","volume":"43","author":"V\u00e1zquez-Del Mercado","year":"2021","journal-title":"Immunopharmacol Immunotoxicology"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1021\/BI00519A023","article-title":"Mechanism of protein stabilization by glycerol: preferential hydration in glycerol-water mixtures","volume":"20","author":"Gekko","year":"1981","journal-title":"Biochemistry"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2013.118","article-title":"The spectrum of MOG autoantibody-associated demyelinating diseases","volume":"9","author":"Reindl","year":"2013","journal-title":"Nat Rev Neurol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/J.JIM.2021.112957","article-title":"Impact of complement and difference of cell-based assay and ELISA in determination of neutralization capacity against mumps and measles virus","volume":"490","author":"Brgles","year":"2021","journal-title":"J Immunol Methods"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/J.JNEUROIM.2021.577757","article-title":"Anti-FGFR3 antibody epitopes are functional sites and correlate with the neuropathy pattern","volume":"361","author":"Tholance","year":"2021","journal-title":"J Neuroimmunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/FIMMU.2018.00097","article-title":"A new classification system for IgG4 autoantibodies","volume":"9","author":"Koneczny","year":"2018","journal-title":"Front Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/FNMOL.2020.00159","article-title":"Myasthenia gravis with antibodies against muscle specific kinase: An update on clinical features, pathophysiology and treatment","volume":"13","author":"Cao","year":"2020","journal-title":"Front Mol Neurosci"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000696","article-title":"Neurologic syndromes related to anti-GAD65: Clinical and serologic response to treatment","volume":"7","author":"Mu\u00f1oz-Lopetegi","year":"2020","journal-title":"Neurology(R) Neuroimmunology Neuroinflamm"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000639","article-title":"Antibodies to neurofascin, contactin-1, and contactin-associated protein 1 in CIDP: Clinical relevance of IgG isotype","volume":"7","author":"Cortese","year":"2019","journal-title":"Neurology(R) Neuroimmunology Neuroinflamm"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.972161\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T01:06:32Z","timestamp":1666227992000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.972161\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,20]]},"references-count":27,"alternative-id":["10.3389\/fimmu.2022.972161"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.972161","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,20]]},"article-number":"972161"}}